CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2209-2216

  Xie, Li ^a   Wei, Jia ^a   Qian, Xiaoping ^a   Chen, Gang ^a   Yu, Lixia ^a   Ding, Yitao ^a   Liu, Bao Rui ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

CXCR4; Docetaxel sensitivity; Gastric cancer

Indexed keywords

CADHERIN; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE 6; DOCETAXEL; MESSENGER RNA; PLERIXAFOR; PROTEINASE; UNCLASSIFIED DRUG; USP15 PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE CULTURE CELL; TISSUE LEVEL;

BIOLOGICAL MARKERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTORS, CXCR4; STOMACH NEOPLASMS; TAXOIDS;

EID: 77955064519     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18): 2903-2909, 2006. (Pubitemid 46630593)
2. Ramaswamy B and Puhalla S: Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc) 42(4): 265-279, 2006.
3. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C and Van CE: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22): 3205-3209, 2007. (Pubitemid 47333732)
4. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D and Rosell R: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25(19): 2747-2754, 2007.
5. Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR and Zheng MH: Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 123(10): 2384-2389, 2008.
6. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R and Liu B: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98(8): 1398-1402, 2008.
7. Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y and Shimada H: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 119(2): 406-413, 2006. (Pubitemid 43911907)
8. Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di LA and Dumontet C: Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14(14): 4511-4516, 2008.
9. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF and Pusztai L: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102(23): 8315-8320, 2005. (Pubitemid 40800086)
10. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8: 97, 2008.
11. De Ligio JT, Velkova A, Zorio DA and Monteiro AN: Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 9(5): 543-549, 2009.
12. Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH and Heo DS: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 20(8): 1414-1419, 2009.
13. Wang T, Wei J, Qian X, Ding Y, Yu L and Liu B: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 262(2): 214-222, 2008.
14. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, Moossa AR and Hoffman RM: Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20(3B): 2049-2054, 2000.
15. Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P and Cognetti F: Docetaxel in advanced gastric cancer - review of the main clinical trials. Acta Oncol 42(7): 693-700, 2003.
16. Hassan S, Baccarelli A, Salvucci O and Basik M: Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res 14(2): 446-454, 2008.
17. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada K and Saiki I: Blocking of the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 44(7): 1022-1029, 2008.
18. Burger JA and Peled A: CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23(1): 43-52, 2009.
19. Bertolini F, Dell AC, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G and Martinelli G: CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 62(11): 3106-3112, 2002. (Pubitemid 34602402)
20. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW and Kavallaris M: Alterations in γ-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst 98(19):1363-1374, 2006.
21. Miller RJ, Banisadr G and Bhattacharyya BJ: CXCR4 signaling in the regulation of stem cell migration and development. J Neuroimmunol 198(1-2): 31-38, 2008.
22. Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I and Van Laethem JL: High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 100(9): 1444-1451, 2009.
23. Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, van de Velde CJ, van Vlierberghe RL, Morreau H, Tollenaar RA and Kuppen PJ: Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron 2008.
24. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP and Ghobrial IM: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113(18): 4341-4351, 2009.
25. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M and Konopleva M: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24): 6215-6224, 2009.
26. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M and Melillo RM: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67(24): 11821-11829, 2007.
27. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB: Tumour-initiating cells: challenges and opportunities for anticancer drag discovery. Nat Rev Drug Discov 8(10): 806-823, 2009.
28. Wong D and Korz W: Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin Cancer Res 14(24): 7975-7980, 2008.
29. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S and Ciardiello F: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 94(23): 12586-12591, 1997.
30. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J and Febbo PG: A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 7(10): 3141-3149, 2008.
31. Shaikh IA, Brown I, Schofield AC, Wahle KW and Heys SD: Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68(15): 1635-1646, 2008.
32. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M and Smalley KS: The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14(1): 230-239, 2008.
33. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A and Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122(1): 91-99, 2008.
34. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J and Nevins JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med 12(11): 1294-1300, 2006.
35. Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T and Xu L: Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7(7): 2192-2202, 2008.